Relevant concomitant care permitted or prohibited during the trial
Treatment with any or all of the following therapies is permitted during the participating studies and not a reason to withhold study medication: deep vein thrombosis prophylaxis with UFH or low molecular weight heparin (LMWH); ‘full’ therapeutic dose UFH or LMWH for a recognised clinical indication; non-heparin anticoagulants; anti-thrombotic medications; protamine; prone positioning; and inhaled nitric oxide. There are no prohibitions during the trial.